Literature DB >> 11954871

Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies.

G J D Hengstman1, R Brouwer, W T M Vree Egberts, H P Seelig, P J H Jongen, W J van Venrooij, B G van Engelen.   

Abstract

The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic diseases that include the familiar disease entities of dermatomyositis (DM), polymyositis (PM), and inclusion body myositis (IBM). A subset of patients has unique autoantibodies which are specific for IIM (myositis specific autoantibodies; MSAs). We studied the clinical and serological characteristics of IIM in 125 Dutch patients. Sera were analysed by immunoblotting, enzyme-linked immunosorbent assay, and immunoprecipitation. The most frequently encountered MSA was the anti-Jo-1 autoantibody (20%), followed by anti-tRNAHis (6%), anti-Mi-2 (6%), and anti-SRP (4%). The presence of certain MSAs was clearly associated with specific clinical characteristics. Anti-Jo-1 and anti-tRNAHis were associated with the anti-synthetase syndrome, anti-SRP with PM with severe myalgia and arthralgia and a moderate response to immunosuppressive treatment. A novel finding was the presence of anti-Mi-2, not only in DM, but also in PM. MSAs were frequently present in DM/PM sera, but were hardly ever detected in the sera of IBM patients. The few IBM patients with MSAs demonstrated a significant response to immunosuppressive treatment. It can be concluded that MSAs define specific clinical syndromes within the spectrum of IIM and that they can assist in the differential diagnosis and treatment plan of these enigmatic disorders by virtually excluding IBM by their presence, and by potentially identifying a subgroup of steroid-responsive IBM patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11954871     DOI: 10.1007/pl00007850

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen.

Authors:  G J D Hengstman; W T M Vree Egberts; H P Seelig; I E Lundberg; H M Moutsopoulos; A Doria; M Mosca; J Vencovsky; W J van Venrooij; B G M van Engelen
Journal:  Ann Rheum Dis       Date:  2006-02       Impact factor: 19.103

2.  High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders.

Authors:  G J D Hengstman; L van Brenk; W T M Vree Egberts; E L van der Kooi; G F Borm; G W A M Padberg; W J van Venrooij; B G M van Engelen
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

Review 3.  Myositis specific autoantibodies.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

4.  Long-term outcome in polymyositis and dermatomyositis.

Authors:  I M Bronner; M F G van der Meulen; M de Visser; S Kalmijn; W J van Venrooij; A E Voskuyl; H J Dinant; W H J P Linssen; J H J Wokke; J E Hoogendijk
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

5.  Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy.

Authors:  G J D Hengstman; H J ter Laak; W T M Vree Egberts; I E Lundberg; H M Moutsopoulos; J Vencovsky; A Doria; M Mosca; W J van Venrooij; B G M van Engelen
Journal:  Ann Rheum Dis       Date:  2006-05-05       Impact factor: 19.103

Review 6.  B-cell survival factors in autoimmune rheumatic disorders.

Authors:  Sandra A Morais; Andreia Vilas-Boas; David A Isenberg
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-08       Impact factor: 5.346

7.  Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study.

Authors:  Cécile Picard; Thierry Vincent; Jean-Christophe Lega; Sophie Hue; Françoise Fortenfant; Daniela Lakomy; René-Louis Humbel; Joelle Goetz; Nicolas Molinari; Nathalie Bardin; Daniel Bertin; Catherine Johanet; Pascale Chretien; Sylvain Dubucquoi; Nathalie Streichenberger; Sophie Desplat-Jégo; Xavier Bossuyt; Jean Sibilia; Isabelle Abreu; Alain Chevailler; Nicole Fabien
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

8.  Inflammatory myopathy with anti-SRP antibodies: case series of a South Australian cohort.

Authors:  Sajini K Basnayake; Peter Blumbergs; Ju Ann Tan; Peter J Roberts-Thompson; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2014-02-05       Impact factor: 2.980

Review 9.  Immune-Mediated Necrotizing Myopathy.

Authors:  Iago Pinal-Fernandez; Maria Casal-Dominguez; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2018-03-26       Impact factor: 4.592

Review 10.  The Clinical Features of Myositis-Associated Autoantibodies: a Review.

Authors:  Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.